宫颈癌
宫颈癌是一种发生在女性生殖系统中宫颈部位的恶性肿瘤。宫颈癌的主要病因是人乳头状瘤病毒(HPV)感染,尤其是HPV的高危型别,如HPV 16和18型。其他相关的危险因素包括抽烟、多个性伴侣、性生活开始过早、多孕多产以及免疫功能缺陷等。宫颈癌的临床表现随着疾病的进展而变化,早期可能没有症状,但随着病情发展,可能出现接触性出血、异常阴道流血等症状。
在宫颈癌的治疗方面,根据癌症的分期和患者的具体情况,常用的治疗手段包括手术、放疗、化疗、靶向治疗和免疫治疗。手术通常适用于早期宫颈癌,而放疗和化疗则常用于中晚期宫颈癌的治疗。靶向治疗和免疫治疗是近年来新兴的治疗方法,主要用于复发或晚期宫颈癌的治疗。
宫颈癌药物研发的目前多集中在以下几个方向:
- 免疫检查点抑制剂:PD1/L1抑制剂如帕博利珠单抗(PD-1抑制剂)已被美国FDA批准用于化疗期间或后疾病进展的复发性或转移性宫颈癌的治疗。此外,帕博利珠单抗联合化疗也被批准用于肿瘤表达PD-L1的持续性、复发性或转移性宫颈癌患者的一线治疗。
- 抗体药物偶联物(ADCs):Tisotumab Vedotin(TV)是首个获批治疗宫颈癌的ADC药物,用于在化疗期间或化疗后病情进展的复发性或转移性宫颈癌患者。TV的宫颈癌二线治疗的Ⅲ期innovaTV301试验显示,相比传统化疗,TV能显著降低死亡风险并改善患者的总生存期(OS)。
- 双特异性抗体:国内企业自主研发的靶向PD-1和CTLA-4的双特异性抗体凯得宁单抗(Cadonilimab,AK104)已申请上市,用于复发或转移性宫颈癌的治疗,并获得了优先审评。
宫颈癌药物靶点
- ALPP
- AXL
- CA9
- CCR8
- CD22
- CD226
- CD247
- CD274
- CEACAM5
- CEACAM6
- CSF2RA
- CSF3R
- CTLA4
- DRD4
- E6
- E7
- EGFR
- ENTPD1
- ERBB2
- ERBB3
- fapA
- FLT1
- FLT3
- FOLR1
- HAVCR2
- ICOS
- IGF1R
- IL12A
- IL12RB1
- IL15RA
- IL17A
- IL2
- IL2RA
- IL2RB
- IL2RG
- ITGB6
- LAG3
- LAIR1
- LILRB1
- LILRB2
- LILRB4
- MUC16
- NECTIN4
- NT5E
- NTN1
- PDCD1
- PTCRA
- STING1
- TACSTD2
- TF
- TGFB1
- TGFB2
- TIGIT
- TNFRSF1A
- TNFRSF1B
- TNFSF9
- TOP1
- VEGFA
宫颈癌药物靶点相关产品推荐
● 靶点蛋白
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP878942HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
CSB-MP007763HU
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP675446HU
HFACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155.
CSB-MP007479HU
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
CSB-MP007765HU
Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized TFRC (CSB-MP3648HU)at 2μg/mL can bind Human TF,the EC50 is 58.72-77.84 ng/mL.
● 稳定细胞株
CHOK1/Human CCR8 Stable Cell Line
CSB-SC004847HU2
Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (CSB-RA004847A1HU) (2µg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
CT26/Human CCR8 Stable Cell Line
CSB-SC004847HU3
Untransfected CT26 cells (green line) and transfected Human CCR8 CT26 Stable cells (red line) were stained with anti-CCR8 antibody (2µg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
CHOK1/Mouse CCR8 Stable Cell Line
CSB-SC004847MO
Untransfected CHO-K1 cells (green line) and transfected Mouse CCR8 CHO-K1 Stable cells (red line) were stained with anti-Mouse CD198-PE antibody (2µg/1*106 cells) and analyzed with flow cytometry.
● 重组抗体
CSB-RA183247A0HU
Overlay Peak curve showing HepG2 cells surface stained with CSB-RA183247A0HU (red line) at 1:50.
CSB-RA004847A1HU
Untransfected HEK293T cells surface (green line) and transfected Human CCR8 HEK293T stable cells surface (red line) were stained with anti-CCR8 antibody (2µg/1*106 cells)。
CSB-RA005165MA3HU
Overlay Peak curve showing Hela cells surface stained with CSB-RA005165MA3HU (red line) at 1:100.
CSB-RA159341A0HU
Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.
产品名称 | 货号 | 靶点 | 反应种属 | 应用范围 |
---|---|---|---|---|
ALPP Recombinant Monoclonal Antibody | CSB-RA183247A0HU | ALPP | Human | ELISA, WB, IHC, FC |
CA9 Recombinant Monoclonal Antibody | CSB-RA614990A0HU | CA9 | Human | ELISA, IHC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847A1HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA3HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA2HU | CCR8 | Human | FC |
CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA4HU | CCR8 | Human | FC |
CD22 Recombinant Monoclonal Antibody | CSB-RA962691A0HU | CD22 | Human | ELISA, IHC |
CD247 Recombinant Monoclonal Antibody | CSB-RA244537A0HU | CD247 | Human | ELISA, FC |
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody | CSB-RA007479A1092phHU | EGFR | Human | ELISA, WB |
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody | CSB-RA007479A1068phHU | EGFR | Human | ELISA, WB |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341A0HU | EGFR | Human | ELISA, WB, IHC, IF, FC |
EGFR Recombinant Monoclonal Antibody | CSB-RA794061A0HU | EGFR | Human | ELISA, WB, IHC |
EGFR Recombinant Monoclonal Antibody | CSB-RA159341MA1HU | EGFR | Human | ELISA, IHC, FC |
ENTPD1 Recombinant Monoclonal Antibody | CSB-RA568544A0HU | ENTPD1 | Human | ELISA, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
ERBB3 Recombinant Monoclonal Antibody | CSB-RA937008A0HU | ERBB3 | Human | ELISA, IF |
FLT1 Recombinant Monoclonal Antibody | CSB-RA940669A0HU | FLT1 | Human, Mouse | ELISA, WB, IHC, FC |
IGF1R Recombinant Monoclonal Antibody | CSB-RA011087MA1HU | IGF1R | Human | ELISA, FC |
IL17A Recombinant Monoclonal Antibody | CSB-RA624104MA1HU | IL17A | Human | ELISA |
IL2RA Recombinant Monoclonal Antibody | CSB-RA011649MA1HU | IL2RA | Human | ELISA, IF |
MUC16 Recombinant Monoclonal Antibody | CSB-RA941216A0HU | MUC16 | Human | ELISA, IHC |
MUC16 Recombinant Monoclonal Antibody | CSB-RA973154A0HU | MUC16 | Human | ELISA, IHC |
NECTIN4 Recombinant Monoclonal Antibody | CSB-RA822274A0HU | NECTIN4 | Human | ELISA |
NT5E Recombinant Monoclonal Antibody | CSB-RA978310A0HU | NT5E | Human | ELISA, IHC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |